Baloxavir: First Global Approval.

Article Details

Citation

Copy to clipboard

Heo YA

Baloxavir: First Global Approval.

Drugs. 2018 Apr;78(6):693-697. doi: 10.1007/s40265-018-0899-1.

PubMed ID

29623652 [ View in PubMed

]

Abstract

Baloxavir marboxil (Xofluza; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.

DrugBank Data that Cites this Article

Drugs

Baloxavir marboxil

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Baloxavir marboxil	Cytochrome P450 2B6	Protein	Humans	Unknown	Inhibitor	Details
Baloxavir marboxil	Cytochrome P450 2C8	Protein	Humans	Unknown	Inhibitor	Details
Baloxavir marboxil	Cytochrome P450 3A4	Protein	Humans	No	Substrate Inhibitor	Details

Drug Transporters

Drug	Transporter	Kind	Organism	Pharmacological Action	Actions
Baloxavir marboxil	ATP-binding cassette sub-family G member 2	Protein	Humans	Unknown	Inhibitor	Details
Baloxavir marboxil	P-glycoprotein 1	Protein	Humans	Unknown	Substrate Inhibitor	Details

Drug Reactions

Reaction
Baloxavir marboxil DB13997 Baloxavir DB15675	Details